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(4) Medical Equipment Evaluation. This
programme's aims are to establish and
promote international protocols and
standards for Performance Testing,
Quality Assurance, Safety and
Environmental aspects.
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CURRENT STATUS OF SYSTEMATIC
RADIOPHARMACEUTICALS FOR
THE TREATMENT OF PAINFUL
METASTATIC BONR DISEASE
C. Pirich
Department of Nuclear Medicine, Vienna
University Hospital, Austria
Intractable bone pain secondary to bone
metastasis from prostate or breast cancer, or
other malignancies is a major problem in the
management of the oncological patient.
Treatment often includes the use of analgesic
drug therapy; however, radiation therapy,
hormonal therapy, chemotherapy, and surgery
mayaiso be needed. Advances in systemic
radionuciide therapy have increased the number
of treatment options available for patients with
painful osseous metastases. This treatment
modality offers three major advantages L) by
addressing all sites of involvement; and ii) by
limiting irradiation of normai tissues due to
selective absorption into bone which results in
an improved therapeutic ratio. Patients with a
positive bone scan are eligible for treatment,
and indications and contraindications for use are
well defined. Large, prospectively randomized
c1inical triais have established the efficacy of
samarium-153 EDTMP and strontium-89 CI as a
first-line therapy. When these agents are used,
pain relief often occurs rapidly and lasts several
weeks to months with responses seen in 60-
80% of patients, depending on the extent and
stage of the disease. With the introduction of
modern bone-seeking radiopharmaceuticals as
Sm-153 EDTMP toxicity is rare and restricted to
reversible myelosuppression. In summary,
evidenced based Iiterature suggests that these
radiopharmaceuticals can significantly reduce
pain and analgesic requirements, improve
quality of life, reduce lifetime radiotherapy
requirements and management costs, and may
even slow the progression of painful metastatic
lesions. Retreatment is safe and effective.
Rep. Pract. Oncol. Radiother. 6 (1) 2001
23.
PRINCIPLES OF RADIOIODINE
TREATMENT C31 I) FOR PATIENTS
WITH DIFFERENTIATED THYROID
CARCINOMAS
Jerzy Sowiński
Klinika Endokrynologii, Szpital kliniczny Nr 2,
Poznań
The aims of radioiodine C31 I) therapy for
patients with differentiated thyroid carcinomas:
D Destruction of thyroid tissue remaining after
thyroidectomy
D Destruction of microcarcinoma focus in site
of thyroid
D Destruction of metastases in Iymph nodes
D Destruction of distant metastases
Therapeutic indications for radioiodine
C31 I) treatment in differentiated thyroid
carcinomas
D Complementary treatment
This treatment is recommended in all patients
with follicular or papillary carcinomas in stage
pT1b-4 NO' 1 Mo after total thyroidectomy. In some
cases it could be as the complementary
treatment after incomplete thyroidectomy.
The recommended radioiodine activity for the
complementary therapy is from 1.75 to 3.5 GBq
(60 - 150 mCi)
D Radical treatment
This kind of treatment is recommended for
patients with differentiated thyroid carcinomas
and remote metastases. If the lesions
concentrate 131 I in quantities sufficient for
radical treatment - the patient can be treated
with the isotope.
D Palliative treatment
Palliative treatment is recommended for patients
with inoperable thyroid carcinoma or with local
recurrence, or with remote metastases
concentrating radioiodine in quantities non
sufficient for radical treatment.
Contraindications for radioiodine C31 I)
treatment
D Pregnancy
D Breast-feeding
The contraception for women is necessary
during 12 months after radioiodine treatment.
For men the 4 - 6 months contraception is
recommended.
Method of radioiodine C31 I) administration
D Patient serum TSH concentration should be
above 30 ulU/mi
37
